Laird Norton Wetherby Wealth Management LLC Increases Stock Position in Genmab A/S (NASDAQ:GMAB)

Laird Norton Wetherby Wealth Management LLC raised its position in shares of Genmab A/S (NASDAQ:GMAB) by 17.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,711 shares of the company’s stock after buying an additional 2,023 shares during the period. Laird Norton Wetherby Wealth Management LLC’s holdings in Genmab A/S were worth $286,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Hudson Bay Capital Management LP boosted its position in Genmab A/S by 103.8% during the 4th quarter. Hudson Bay Capital Management LP now owns 540,000 shares of the company’s stock valued at $11,270,000 after buying an additional 275,000 shares during the period. Graham Capital Management L.P. boosted its position in Genmab A/S by 38.2% during the 4th quarter. Graham Capital Management L.P. now owns 55,417 shares of the company’s stock valued at $1,157,000 after buying an additional 15,321 shares during the period. Deep Track Capital LP bought a new position in Genmab A/S in the 4th quarter worth $41,740,000. Cubist Systematic Strategies LLC bought a new position in Genmab A/S in the 4th quarter worth $12,360,000. Finally, Bridger Management LLC bought a new position in Genmab A/S in the 4th quarter worth $6,084,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Truist Financial decreased their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Finally, Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $39.17.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $19.88 on Friday. The company has a 50-day moving average of $19.74 and a 200 day moving average of $20.77. The firm has a market cap of $12.75 billion, a price-to-earnings ratio of 11.43, a PEG ratio of 2.65 and a beta of 1.04. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $30.06.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The company had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. On average, equities analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.